This review outlines the therapeutic potential and significant translational barriers (regulatory, manufacturing, delivery) for injectable biomaterials in treating myocardial infarction and peripheral artery disease.
No takes yet. Share an insight, caveat, or question.
Barriers limit clinical use of injectable biomaterials; leaves open need for regulatory and manufacturing solutions before trials proceed.
Ungerleider et al. (2014) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: